Durga Borkar, MD: Phase 2 Results of ONL1204 for Rhegmatogenous Retinal Detachment

Published Date: 31 Oct 2024

At AAO 2024, Borkar discusses the visual acuity benefit of ONL1204 ophthalmic solution for patients with macula-off rhegmatogenous retinal detachment.

Read Full News

Latest News

Gene-Agnostic Therapy Sees 3-Year Gain in Severe Vision Loss

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved functional vision in advanced severe vision loss.

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved functional vision in advanced severe vision loss.

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

News All Time

One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk

But it's not time to prescribe tirzepatide outside current indications, expert says

Color Blindness and Bladder Cancer: A Bad Combination for Survival?

Study suggests inability to identify blood in urine may delay diagnosis and reduce survival

Cardiovascular Risk Score Shows Value in Predicting Future Eye Disease

The score is commonly calculated in primary care

People, Faces Appeared Smaller Than Usual in Patient's Rare Case

63-year-old had an atypical cause of Alice in Wonderland Syndrome

Contaminated Water Blamed for 10 Deaths; FDA Rejections; Mammograms for Heart Risks?

Health news and commentary gathered by MedPage Today staff

FDA OKs More Eye Drops That Can Replace Reading Glasses

Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss

Sleeping With Two Pillows May Raise Internal Eye Pressure in Glaucoma

Stacked pillows alter the neck position and may compress the jugular, researchers suggest

Teen Boy Grows a Tooth Between Eyelid and Eyebrow

The 16-year-old underwent surgery to remove an ectopic canine tooth in left eye's superior orbit

Study Adds Fuel to the Debate Over Cataract Surgery and Wet AMD

Earlier concerns about surgery accelerating AMD progression likely overstated, researcher says

Hospital Had Ties to Epstein; Naked Knifeman at Eye Doctor; Health Department Probed

Health news and commentary gathered by MedPage Today staff

Some Blind Fans to Experience Super Bowl With Tactile Device That Tracks Ball

About 10 blind and low-vision fans will have an opportunity to use the technology

CDC Study Warns of Vision-Threatening Eye Infections After Laser Surgery

Three patients at New York City clinic developed fungal keratitis caused by a mold

Dry Eye: Handmaiden to Many Autoimmune Conditions, Not Just Sjogren's Disease

Taiwanese study puts numbers to common but poorly studied phenomenon

Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis

Eye damage remains uncommon after 15 years, but certain factors increase the risk

Glaucoma Checks in Primary Care; Wastewater to Screen for Colorectal Cancer

Also in TTHealthWatch: new cholesterol management guidelines

Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs

First evidence of formulation-specific difference, significantly higher in men than women

Recommended News For You

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

A study on lung cancer provides additional proof of the value of screening.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

Recommended Articles For You

Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer 

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers 

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis 

Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

1.

Respiratory Ramifications of Systemic Disease: A Comprehensive Review

2.

Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery

3.

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review

4.

Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support

5.

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot